XLO Stock Analysis: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$9.17
-0.10 (-1.08%)
âŧ
5d:
+0.66%
30d:
-0.33%
90d:
+17.41%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 13, 2026
3d
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XLO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XLO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $9.17, which is considered slightly high relative to its 30-day fair value range of $8.77 to $9.30. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.5) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a uptrend. Immediate support is located at $8.44, while resistance sits at $9.62.
Market Sentiment: XLO scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+118.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XLO is in a uptrend. Immediate support is located at $8.44, while resistance sits at $9.62.
Market Sentiment: XLO scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+118.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.77 -
$9.30
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.1% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.77 -
$9.30
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.44
Resistance Level
$9.62
Current Trend
Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.54
Wall Street Target
$20.00
(+118.1%)
Revenue Growth (YoY)
331.7%
Profit Margin
-58.5%
PE vs Historical
-3.5 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: August 09, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 34 SELL |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 49 HOLD |